JAKARTA, MAY 25, 2026 – PT Pyridam Farma Tbk (IDX: PYFA) has officially announced the resignation of Robby Yulianto from his position as President Commissioner, effective upon the receipt of his resignation letter on May 20, 2026. PYFA’s management fully respects his decision to step down to pursue other professional endeavors outside the company. The company assures stakeholders that this leadership transition will not materially impact its daily operations, legal standing, financial stability, or overall business continuity.

The management of PYFA extends its deepest gratitude for Yulianto’s dedication, support, and positive contributions since he assumed leadership in 2020. Following his departure, PYFA will initiate a nomination process to propose a new composition for the Board of Commissioners. The new board will be officially announced and appointed at the upcoming General Meeting of Shareholders (GMS), in strict accordance with the company’s Articles of Association and applicable regulations.

“We respect Mr. Robby Yulianto’s decision to focus on other professional opportunities and sincerely thank him for his invaluable contributions to the company’s growth. Moving forward, the company will conduct a nomination process to propose a new Board of Commissioners at the upcoming GMS, complying fully with our Articles of Association,” stated Herdiasti Anggitya Dwisani, Corporate Secretary of PYFA, in an official public disclosure.

Amidst this board transition, PYFA remains steadfast in executing its long-term growth strategy. The company is currently preparing for a major corporate action: a Pre-Emptive Rights Issue.

PYFA plans to issue a maximum of 5.7 billion new shares. The proceeds from this rights issue will be strategically allocated to strengthen the company’s capital structure and fund key investments and acquisitions. This financial move is a cornerstone of PYFA’s expansion roadmap, aimed at accelerating growth and building a globally integrated healthcare ecosystem.

The anticipated capital injection will provide PYFA with the operational agility required to deliver cutting-edge healthcare products and services to the public, while generating sustainable, long-term value for its investors.

Backed by robust corporate fundamentals and strong shareholder support for this corporate action, PYFA’s management remains highly optimistic. The company is well-positioned to solidify its standing as a leading player in the pharmaceutical and healthcare industries, both in Indonesia and on the global stage.

About PYFA

PT Pyridam Farma Tbk, also known as PYFA, is a public pharmaceutical company listed on the Indonesia Stock Exchange (Ticker: PYFA). PYFA operates several business units producing prescription medicines in various forms, including tablets, capsules, creams, and injections. PYFA also has several well-known subsidiaries, including PT Holi Pharma, PT Ethica Industri Farmasi, and Probiotec Multipack.

Media Relations

Leilanie Nadia Kusuma
Head of Corporate Communications
Website : www.pyfa.co.id
Email : corcomm@pyfa.co.id